scholarly article | Q13442814 |
P356 | DOI | 10.1021/ACSMEDCHEMLETT.6B00060 |
P8608 | Fatcat ID | release_4djves6elreyzfbmhjrhmafo6m |
P932 | PMC publication ID | 4868099 |
P698 | PubMed publication ID | 27200176 |
P50 | author | Anne Le | Q40504142 |
P2093 | author name string | Barbara S Slusher | |
Camilo Rojas | |||
Takashi Tsukamoto | |||
Ajit G Thomas | |||
Marigo Stathis | |||
Christopher Nguyen | |||
Sarah C Zimmermann | |||
Brad Poore | |||
Andrew Luu | |||
Emily F Wolf | |||
P2860 | cites work | Full-length human glutaminase in complex with an allosteric inhibitor | Q24295587 |
Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism | Q27678762 | ||
Metabolism and action of amino acid analog anti-cancer agents | Q28298599 | ||
Targeting mitochondrial glutaminase activity inhibits oncogenic transformation | Q34807996 | ||
Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. | Q35836097 | ||
Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth | Q36312149 | ||
Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. | Q36517216 | ||
Dibenzophenanthridines as inhibitors of glutaminase C and cancer cell proliferation. | Q36749597 | ||
Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer. | Q38039199 | ||
Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer | Q39024340 | ||
Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) | Q39253539 | ||
Regulation of glutaminase activity and glutamine metabolism | Q40926056 | ||
Interactions of N-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-2-aryl-2-yl-acetamides and 1-{[2-(4-phenyl-piperazin-1-yl)-ethyl]-phenyl}-3-aryl-2-yl-ureas with dopamine D2 and 5-hydroxytryptamine 5HT(1A) receptors. | Q51759007 | ||
P433 | issue | 5 | |
P921 | main subject | allosteric inhibitor | Q70361704 |
P304 | page(s) | 520-524 | |
P577 | publication date | 2016-03-13 | |
P1433 | published in | ACS Medicinal Chemistry Letters | Q2819061 |
P1476 | title | Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold | |
P478 | volume | 7 |
Q38767151 | A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis |
Q37247525 | Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer |
Q51138025 | Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators. |
Q54978523 | Inhibition of Glycolysis and Glutaminolysis: Emerging Drug Discovery Approach to Combat Cancer. |
Q90642651 | Metabolic Plasticity in Chemotherapy Resistance |
Q89401928 | Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase |
Q37628958 | Structural basis for exploring the allosteric inhibition of human kidney type glutaminase |
Q91669842 | Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer |
Search more.